Cell Therapy: Pharmacological Intervention Enters a Third Era

[1]	FDA approval brings first gene therapy to the United States [Internet]. Silver Spring: US Food and Drug Administration; 2017 Aug 30 [updated 2018 Mar 26; cited 2018 Jul 22]. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm.

[2]	Bartfai T., Lees G.V.. Drug discovery: from bedside to Wall Street.

[3]	Bartfai T., Lees G.V.. The future of drug discovery: who decides which diseases to treat?.

[4]	Ferrara J.L., Deeg H.J.. Graft-versus-host disease. N Engl J Med. 1991; 324(10): 667-674.

[5]	Rosenberg S.A., Spiess P., Lafreniere R.. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986; 233(4770): 1318-1321.

[6]	Rosenberg S.A., Packard B.S., Aebersold P.M., Solomon D., Topalian S.L., Toy S.T., . Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988; 319(25): 1676-1680.

[7]	Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., . Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006; 314(5796): 126-129.

[8]	Gross G., Waks T., Eshhar Z.. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 1989; 86(24): 10024-10028.

[9]	Kalos M., Levine B.L., Porter D.L., Katz S., Grupp S.A., Bagg A., . T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011; 3(95): 95ra73.

[10]	Brentjens R.J., Davila M.L., Riviere I., Park J., Wang X., Cowell L.G., . T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013; 5(177): 177ra38.

[11]	Maude S.L., Frey N., Shaw P.A., Aplenc R., Barrett D.M., Bunin N.J., . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16): 1507-1517.

[12]	Turtle C.J., Hanafi L.A., Berger C., Gooley T.A., Cherian S., Hudecek M., . CD19 CAR-T cells of defined CD4⁺:CD8⁺ composition in adult B cell ALL patients. J Clin Invest. 2016; 126(6): 2123-2138.

[13]	Lee D.W., Gardner R., Porter D.L., Louis C.U., Ahmed N., Jensen M., . Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2): 188-195.